Oncology Flashcards

1
Q

Management of malignant hypercalcaemia

A

IV 0.9% saline (4-6L, 200-300ml/hr)

Single dose IV bisphosphonates (Zoledronic acid and pamidronate)

IM/SC calcitonin (works quickly)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Causes of malignant hypercalcaemia?

A

Osteolysis (lytic bone metastases)

Humoral (PTHrP in breast cancer or squamous cell lung carcinoma)

Dehydration

Tumour specific mechanisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Presentation of malignant hypercalcaemia

A

Bones, stone, groans and psychic moans

GI: abdo pain, constipation, vomiting, weight loss
Renal: stones, polyuria, polydipsia
Neuro: fatigue, weakness, confusion
Psych: depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Management of malignant spinal cord compression

A

Corticosteroids

Surgical decompression

Radiotherapy (for pain control or if unsuitable for surgery)

Chemotherapy (if chemosensitive tumours)

Hormone deprivation (for newly diagnosed prostate cancer)

Analgesia

VTE prophylaxis and pressure sore prevention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Presentation of SCC

A
Worsening back pain 
Leg weakness
Sensory loss below level of lesion 
Bladder and bowel dysfunction (LATE)
Radicular pain 

LMN signs at level of lesion, UMN below level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

SVC obstruction investigations

A

Clinical
CXR (widened mediastinum or mass on right side of heart)
CT scan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Presentation of SVCO

A
Facial, neck, arm and torso oedema 
Dyspnoea, cough, chest pain at rest
Dilated veins in arms and neck and chest wall
Syncope 
Cyanosis 
Severe respiratory distress
Engorged conjunctiva 
Convulsions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Management of SVCO

A
High dose steroids 
Stenting 
Raise head, give oxygen 
Chemo 
Radiotherapy 
Anticoagulation if central vein thrombosis present
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the SIRS criteria?

A
HR >90
RR >20
BP systolic <90
Urine output less than 0.5-1ml/kg/hr
Temp >38 or <36
Acute confusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When would you get a patient with neutropenic sepsis reviewed by a senior clinician

A

Lactate >2
Evidence of end-organ failure
Haemodynamic instability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Abx treatment of patients with neutropenic sepsis

A

Piperacillin with tazobactam (Tazocin) +/- gentamycin

Switch to oral if improving after 24-48 hours

Consider 2nd line (e.g. meropenem) if no improvement after 48 hours

Consider other cause e.g. fungal (candida) or virus if no improvement after 5 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do you prevent neutropenic sepsis in high risk patients

A

Fluoroquinolones e.g. ciprofloxacin

G-CSF (granulocyte colony-stimulating factor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What two criteria are required for diagnosis of neutropenic sepsis

A

> 38 fever

<0.5-1 x 10^9/L neutrophils

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Most common causative organisms for neutropenic sepsis

A

Staph epidermidis (gram negative, coagulase negative)

Pseudomonas aeruginosa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Most common viral causes of neutropenic sepsis

A
Herpes zoster 
Varicella zoster 
Epstein-Barr 
HSV 
Cytomegalovirus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Acquired causes of neutropenia?

A
Drugs (e.g. carbimazole or chemotherapy)
Infection 
Bone marrow disease 
Autoimmune disease 
Nutritional deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Genetic cause of neutropenia

A

Chediak-Higashi syndrome (autosomal recessive)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Red flags for back pain

A
Recent infection 
<20 or >55 onset 
Thoracic pain 
Immunocompromise 
History of malignancy 
Fevers, chills, unexplained weight loss 
Night back pain, no better when supine 
IV drug use
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Cauda equina presentation

A
LMN signs and symptoms 
Painless urinary retention and overflow incontinence 
Saddle anaesthesia 
Radicular and lower back pain 
Reduced anal tone
Impotence 
Absent ankle jerk 
Asymmetrical weakness
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Most common anatomical region of spinal cord to be affected by malignant spinal cord compression

A

Thoracic

21
Q

Gold standard investigation for spinal cord compression

A

MRI whole spine

22
Q

Most common malignancies to cause malignant spinal cord compression

A
Breast 
Prostate 
Multiple myeloma 
lymphoma 
Lung cancer
23
Q

What collaterals might circumvent a SVCO

A

Azygous
Internal mammary
Long thoracic (femoral and vertebral)

24
Q

Most common cause of SVCO

A

Non-Hodgkin lymphoma

Non-small cell lung carcinoma

25
Q

What is Pemberton’s sign?

A

Raise arms for 1-2 minutes

Increased facial plethora, dilated veins and respiratory distress

26
Q

Investigation of choice for SVCO

A

Contrast-enhanced CT scan - modality of choice
X-ray may be initially given (widening mediastinum and pleural effusion)
Superior vena cavogram (gold standard)

27
Q

Causative organism of fibrosing mediastinitis

A

Histoplasmosis infection

Can cause SVCO

28
Q

What is the most common cause of malignant hypercalcaemia?

A

Tumour release of PTH-related peptide

29
Q

What mediastinal involvement might you see in lung carcinoma

A

Pancoast tumour:
Brachial plexus compression –> shoulder or arm pain, weakness and atrophy
Horner’s syndrome

Pleural effusion: dyspnoea and chest pain

Pericardial effusion

SVCO

30
Q

What are the features of paraneoplastic syndrome?

A

Small Cell:
Ectopic cushing’s - increase in cortisol release from adrenal glands
SIADH: ADH release leading to water retention

Squamous cell:
PTH-rh leading to hypercalcaemia
Hypertrophic pulmonary osteoarthropathy (HPOA) –> clubbing and periosteal proliferation of tubular bone
Hyperthyroidism

Adenocarcinoma:
HPOA
Gynaecomastia
HPOA

31
Q

What findings might you see on CXR in a patient with lung cancer?

A
Hilam enlargement 
Pleural effusion 
Lung collapse 
Rib lesions 
Pulmonary opacity (tumour)
32
Q

Lung cancer investigations

A

CXR
CT

Staging:
Bronchoscopy (primary tumour visualised and sample taken)
CT-guided fine needle biopsy (more reliable)
Needle aspiration
Thomococentesis (fluid from pleural cavity)

PET scan for NSC - determines whether curative treatment
Bloods - thrombocytosis, leukocytosis

33
Q

Management of lung carcinoma according to staging?

A

Surgery for I and II

Chemo (increases survival by a year) and radiotherapy for III

Laser therapy and stenting (managing airway obstruction)

34
Q

When would you refer a patient using suspected cancer pathway>

A

Over 40 and unexplained haemoptysis

CXR findings suggestive of lung cancer

35
Q

When would you offer a patient CXR within 2 weeks?

A

Over 40 and two of the following or smoked before and one of the following:

Cough 
Fatigue 
SOB 
Weight loss 
Chest pain 
Appetite loss 
CONSIDER if:
Lymphadenopathy 
Clubbing 
Thrombocytosis 
Chest signs consistent with lung cancer 
Recurrent chest infections
36
Q

Which lung cancers are not related to smoking?

A

Adenocarcinoma and alveolar cell carcinoma +++sputum

37
Q

What are the features of the three types of non-small cell carcinoma?

A
Squamous cell: 
Central 
PTH-rP secretion 
Clubbing 
HPOA

Adenocarcinoma:
Peripheral
Non-smokers

Large cell:
Peripheral
Anaplastic, poorly differentiated, poor prognosis
Beta hCG production

38
Q

What features is small cell carcinoma associated with?

A

ADH –> hyponatraemia
ACTH –> Cushing’s, adrenal hyperplasia and hypokalaemic acidosis
Lambert-Eaton myasthenic syndrome

39
Q

What might cause a false positive PSA?

A

Prostatitis
UTI
BPH
Vigorous DRE

40
Q

What % of free:total PSA suggests cancer?

A

<20% –> biopsy advised

41
Q

What nodes are most likely to be affected by prostate cancer spread?

A

Obturator nodes

42
Q

Management of localised (T1/T2) prostate cancer?

A

Watchful waiting: elderly, co-morbidities, low Gleason score

Surgical: prostatectomy and obturator node excision. Risk of ED

Radiotherapy: risk of rectal malignancy and radiation proctatitis. Use of brachytherapy. Potentially curative

Active surveillance: T1c, Gleason 3+3, PSA <0.15, cancer in less than 50% of biopsy cores

43
Q

Management of localised advanced (T3/T4) prostate cancer?

A

hormonal therapy

radical prostatectomy: risk of ED

radiotherapy: external beam and brachytherapy. risk of bladder, colon, and rectal cancer

44
Q

Management of metastatic prostate cancer?

A

Hormonal therapy:

Synthetic GnRH agonist
e.g. Goserelin (Zoladex)
cover initially with anti-androgen to prevent rise in testosterone

Anti-androgen
cyproterone acetate

Orchidectomy

45
Q

Preferred treatment for cancer associated thrombosis?

A

Dalteparin

46
Q

Management of brain mets

A

Dexamethason (8g)
PPI to protect stomach
Anti-emetics

47
Q

What three conditions are associated with bone sclerosis (increased density)

A

Metastatic prostate and breast carcinoma

Sickle cell disease

48
Q

Which cancers commonly cause bony tumour deposits

A
Myeloma 
Melanoma 
Thyroid 
Renal
Prostate 
Lung 
Breast